Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 1948-1952

  Dajcs, Joseph J ^a   Thibodeaux, Brett A ^a   Marquart, Mary E ^a   Girgis, Dalia O ^a   Traidej, Mullika ^a   O'Callaghan, Richard J ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA; DRUG EFFICACY; KERATITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; CORNEA; DRUG RESISTANCE, BACTERIAL; KERATITIS; OFLOXACIN; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS;

EID: 2542498885     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.1948-1952.2004     Document Type: Article

References (27)

1. Adams, D. E., E. M. Shekhtman, E. L. Zechiedrich, M. B. Schmidt, and N. R. Cozzarelli. 1992. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 71:277-288.
2. Alexandrakis, G., E. C. Alfonso, and D. Miller. 2000. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 107:1497-1502.
3. Biedenbach, D. J., and R. N. Jones. 1996. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn. Microbiol. Infect. Dis. 25:47-51.
4. Blanche, F., B. Cameron, F. X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720.
5. Callegan, M. C., J. A. Hobden, J. M. Hill, M. S. Insler, and R. J. O'Callaghan. 1992. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Investig. Ophthalmol. Vis. Sci. 33: 3017-3023.
6. Chusid, M. J., and S. D. Davis. 1979. Experimental bacterial keratitis in neutropenic guinea pigs: polymorphonuclear leukocytes in corneal host defense. Infect. Immun. 24:948-952.
7. Dajcs, J. J., E. B. Hume, J. M. Moreau, A. R. Caballero, B. M. Cannon, and R. J. O'Callaghan. 2000. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Investig. Ophthalmol. Vis. Sci, 41:1432-1437.
8. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
9. Davis, R., and H. M. Bryson. 1994. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47:677-700.
10. Dholakia, N., K. V. Rolston., D. H. Ho, B. LeBlanc, and G. P. Bodey. 1994. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob. Agents Chemother. 38:848-852.
11. Fasching, C. E., F. C. Tenover, T. G. Slama, L. M. Fisher, S. Sreedharan, M. Oram, K. Willard, L. M. Sinn, D. N. Gerding, and L. R. Peterson. 1991. gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee. J. Infect. Dis. 164:976-979.
12. Goldstein, M. H., R. P. Kowalski, Y. J. Gordon. 1999. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 106: 1313-1318.
13. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
14. Kato, J., H. Suzuki, and H. Ikeda. 1992. Purification and characterization of DNA topoisomerase IV in Escherichia coli. J. Biol. Chem. 267:25676-25684.
15. Liesegang, T. J. 1998. Bacterial and fungal keratitis, p. 159-219. In H. E. Kaufman (ed.), The cornea, 2nd ed. Butterworth-Heinemann, Boston, Mass.
16. Lister, P. D. 2001. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin. Infect. Dis. 32:S33-S38.
17. Mather, R., L. M. Karenchak, E. G. Romanowski, and R. P. Kowalski. 2002. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am. J. Ophthalmol. 133:463-466.
18. O'Brien, F. G., J. W. Pearman, M. Gracey, T. V. Riley, and W. B. Grubb. 1999. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J. Clin. Microbiol. 37:2858-2862.
19. O'Callaghan, R. J., M. C. Callegan, J. M. Moreau, L. C. Green, T. J. Foster, O. M. Hartford, L. S. Engel, and J. M. Hill. 1997. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect. Immun. 65:1571-1578.
20. O'Reilly, M., B. Kreiswirth, and T. J. Foster. 1990. Cryptic alpha-toxin gene in toxic shock syndrome and septicemia strains of Staphylococcus aureus. Mol. Microbiol. 11:1947-1955.
21. Ormerod, L. D., E. Hertzmark, D. S. Gomez, R. G. Stabiner, D. J. Schanzlin, and R. E. Smith. 1987. Epidemiology of microbial keratitis in southern California. A multivariate analysis. Ophthalmology 94:1322-1333.
22. Peterson, D. L. 1999. Vancomycin-resistant Staphylococcus aureus. Infect. Med. 16:235-238.
23. Shen, L. L. 1994. Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials. Adv. Pharmacol. 29A:285-304.
24. Souli, M., C. B. Wennersten, and G. M. Eliopoulos. 1998. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int. J. Antimicrob. Agents 10:23-30.
25. Takei, M., H. Fukuda, R. Kishii, and M. Hosaka. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.
26. Wang, J. C. 1991. DNA topoisomerases: why so many? J. Biol. Chem. 266:6659-6662.
27. Wright, D. H., B. W. Gunderson, L. B. Hovde, G. H. Ross, K. H. Ibrahim, and J. C. Rotschafer. 2002. Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob. Agents Chemother. 46:1561-1563.